Target intelligence / Profile preview

30S ribosomal subunit (Helicobacter pylori) (30S subunit)

Target
30S subunit
Molecular classification
Ribonucleoprotein complex, Ribosome, Enzyme
01

Overview

The 30S ribosomal subunit of Helicobacter pylori is a vital ribonucleoprotein complex responsible for the initiation and accuracy of bacterial protein synthesis [5, 9]. It consists of the 16S ribosomal RNA (rRNA) and approximately 21 ribosomal proteins, which together facilitate the decoding of genetic information by ensuring correct codon-anticodon pairing between mRNA and tRNA [4, 5]. This subunit is a major therapeutic target for several classes of antibiotics, including tetracyclines and aminoglycosides, which are used to treat H. pylori infections [1, 13]. Tetracyclines inhibit translation by binding to the 30S subunit and blocking the entry of aminoacyl-tRNA into the ribosomal A-site, while aminoglycosides can induce mRNA misreading or inhibit translocation [8, 13, 16]. Resistance to these treatments is a significant clinical challenge, often arising from specific point mutations in the 16S rRNA gene that alter the antibiotic binding site [1, 8, 16]. Eradication of H. pylori is essential for preventing and treating associated diseases such as chronic gastritis, peptic ulcers, and gastric adenocarcinoma [7, 10, 19]. The subunit's structural conservation across bacteria makes it a broad-spectrum target, yet specific variations in H. pylori influence its susceptibility and resistance profiles [13, 16].

Other names
Small ribosomal subunit30S subunit16S rRNA-protein complex
02

Mechanism of action

Inhibition of bacterial protein synthesis by binding to the 30S subunit, which blocks the attachment of aminoacyl-tRNA to the A-site (tetracyclines) or induces mRNA misreading and inhibits translocation (aminoglycosides) [8, 13, 16].

03

Biological functions

Protein synthesisTranslation initiationDecodingTranslocation
04

Disease associations

Helicobacter pylori infectionGastritisPeptic ulcer diseaseGastric cancerMucosa-associated lymphoid tissue (MALT) lymphoma
05

Safety considerations

Development of antibiotic resistance [1, 15, 16]Disruption of the gastrointestinal microbiome [10]Potential for systemic side effects (e.g., nephrotoxicity or ototoxicity with certain aminoglycosides) [18]
06

Interacting drugs

Tetracycline [1, 15]

9 more in the full profile.

07

Biomarkers

16S rRNA gene mutations (e.g., AGA926-928TTC) [8, 16]16S rRNA sequence variants [11, 17]

Beyond the preview

Go deeper on 30S ribosomal subunit (Helicobacter pylori) (30S subunit).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 30S ribosomal subunit (Helicobacter pylori) (30S subunit).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call